Across TCGA pan-cancer cohorts, SEMA4B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SEMA4B data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SEMA4B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SEMA4B expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, ESCA, and UCEC are the cancer types where SEMA4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	1.000	0.328	.015	12	view →
ESCA	DFS	Median	II,III,IV	0.173	0.525	.017	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	OS	Median	All	0.191	0.710	.021	6	view →
SKCM	DFS	Median	III,IV	0.015	0.648	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SEMA4B tumor-vs-normal RNA expression · all SEMA4B data types